Mustophoran (Fotemustine)

Fotemustine exerts its antineoplastic effect by alkylating DNA at the O‑6 position of guanine, creating cross‑links that block DNA replication and transcription. The resulting DNA damage triggers cell‑cycle arrest and apoptosis, preferentially affecting rapidly dividing tumor cells while sparing most normal tissues.

The dosing regimen for Mustophoran is individualized by the treating oncologist based on factors such as tumor type, patient weight, renal and hepatic function, and prior therapies. Physicians calculate the appropriate intravenous infusion volume and schedule, and the exact dose is recorded in the patient’s prescription.

Safety data for fotemustine in pregnancy and lactation are limited, and the drug is classified as contraindicated for use in pregnant or nursing women because of its potential teratogenic and cytotoxic effects. Women of child‑bearing potential should use effective contraception during treatment and for a defined period after the last dose.

To request Mustophoran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity and providing institutional credentials. GNH India works with hospitals, pharmacies and procurement teams worldwide, then replies with pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

Compared with older nitrosoureas such as carmustine, fotemustine offers higher lipophilicity, allowing better penetration of the blood‑brain barrier and potentially improved activity against intracranial tumors. However, both classes share similar toxicity profiles, and choice of agent depends on tumor characteristics, prior treatment history and individual patient tolerance.

Mustophoran must be stored refrigerated at 2‑8 °C in its original packaging, protected from light and moisture. The solution should not be frozen or shaken vigorously. Prior to administration, the product may be allowed to reach room temperature, but any visible particles or discoloration requires discarding.

Mustophoran is supplied as an injectable solution for intravenous infusion. The infusion is typically given over a period of 30‑60 minutes under sterile conditions in a clinical setting. Dosage and frequency are determined by the prescribing oncologist, and patients are monitored for infusion‑related reactions during and after administration.

The most serious adverse events linked to fotemustine include severe myelosuppression leading to infection or bleeding, pulmonary fibrosis that can cause progressive respiratory failure, and hemorrhagic cystitis with potential urinary tract complications. Prompt recognition and supportive care are essential, and treatment should be discontinued if life‑threatening toxicity occurs.

Mustophoran is contraindicated in patients with known hypersensitivity to fotemustine or other nitrosoureas, those with severe bone‑marrow suppression, uncontrolled infections, or significant pulmonary disease such as active interstitial pneumonitis. Caution is also advised in individuals with impaired hepatic or renal function, and it should not be used in pregnant or nursing women.